文献速递浆细胞疾病

新诊断多发性骨髓瘤中基于微小残留病应答调整的治疗(MASTER):多中心、单臂、2期试验最终报告

Minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma (MASTER): final report of the multicentre, single-arm, phase 2 trial.
PubMed 文献 · Lancet Haematol · 2023-09-27

MASTER是一项在美国5个学术医学中心开展的多中心、单臂、2期试验,评估达雷妥尤单抗、卡非佐米、来那度胺和地塞米松(Dara-KRd)方案根据MRD状态调整治疗时长与停药策略的疗效。123例新诊断多发性骨髓瘤患者中,118例可评估MRD,96例(81%,95%CI 73-88)达到MRD阴性(<10⁻⁵),84例(71%,62-79)达到MRD-SURE并停止治疗。无高危染色体异常、1个高危染色体异常和≥2个高危染色体异常患者的36个月无进展生存率分别为88%(95%CI 78-95)、79%(67-88)和50%(30-70)。

要点

  • 118例可评估MRD患者中96例(81%)达到MRD阴性(<10⁻⁵),84例(71%)达到MRD-SURE并停止治疗。
  • ≥2个高危染色体异常患者36个月无进展生存率为50%(95%CI 30-70),停药后24个月累积进展发生率为47%(95%CI 23-72)。
  • 截至2023年2月7日,61例患者(占118例MRD可评估者的52%,占84例达到MRD-SURE者的73%)保持无治疗且MRD阴性。

核心结论

  • 该基于MRD状态调整治疗时长与停药的方法在大多数新诊断多发性骨髓瘤患者中提供了良好结局和停止治疗的路径。
  • 超高危多发性骨髓瘤患者(定义为≥2个高危染色体异常)的结局仍不令人满意,应优先纳入早期引入新机制作用药物的试验。

研究设计与样本

  • MASTER为在美国5个学术医学中心开展的多中心、单臂、2期试验,纳入≥18岁新诊断多发性骨髓瘤患者,要求东部肿瘤协作组体能状态0-2分、预期寿命至少12个月,除最多1个周期含硼替佐米、环磷酰胺和地塞米松的治疗外未接受过其他治疗,并富集高危染色体异常患者。
  • 诱导期为4个28天周期的Dara-KRd方案:达雷妥尤单抗16 mg/kg静脉给药(第1、8、15、22天),卡非佐米56 mg/m²静脉给药(第1、8、15天),来那度胺25 mg口服(第1-21天),地塞米松40 mg口服或静脉给药(第1、8、15、22天);诱导后行自体造血干细胞移植,随后最多2个阶段Dara-KRd巩固治疗。
  • 每个阶段后或期间通过二代测序评估MRD,主要终点为达到MRD阴性(<10⁻⁵);连续2个阶段后或期间达到MRD阴性者停止治疗并进入MRD监测(MRD-SURE),未达到连续2次MRD阴性者接受来那度胺维持治疗;所有分析在意向治疗人群中进行。

主要发现

  • 2018年3月21日至2020年10月23日共纳入123例患者,中位年龄61岁(IQR 55-68),70例(57%)为男性,53例(43%)为女性;53例(43%)无高危染色体异常,46例(37%)有1个高危染色体异常,24例(20%)有≥2个高危染色体异常。
  • 123例中118例(96%)可通过二代测序评估MRD;118例中96例(81%,95%CI 73-88)达到MRD<10⁻⁵,其中无高危染色体异常者39/50例(78%,95%CI 64-88)、1个高危染色体异常者38/44例(86%,95%CI 73-95)、≥2个高危染色体异常者19/24例(79%,95%CI 58-93);84例(71%,95%CI 62-79)达到MRD-SURE并停止治疗。
  • 全部123例患者36个月无进展生存率:无高危染色体异常者88%(95%CI 78-95),1个高危染色体异常者79%(95%CI 67-88),≥2个高危染色体异常者50%(95%CI 30-70)。
  • 84例达到MRD-SURE患者自停止治疗起24个月累积进展发生率:无高危染色体异常者9%(95%CI 1-19),1个高危染色体异常者9%(95%CI 1-18),≥2个高危染色体异常者47%(95%CI 23-72)。
  • 截至2023年2月7日,61例患者(占118例MRD可评估者的52%,占84例达到MRD-SURE者的73%)保持无治疗且MRD阴性;最常见3-4级不良事件为中性粒细胞减少(43例,35%)、淋巴细胞减少(28例,23%)和高血压(13例,11%);记录到3例治疗中出现死亡(2例猝死、1例病毒感染),均判定与治疗无关。

关键数值与推荐

  • 主要终点为达到MRD阴性(<10⁻⁵),通过二代测序评估。
  • 连续2个阶段后或期间达到MRD阴性者停止治疗并进入MRD-SURE监测;未达到连续2次MRD阴性者接受来那度胺维持治疗。

临床怎么用

  • 作者认为,该基于MRD状态调整治疗时长与停药的方法在大多数新诊断多发性骨髓瘤患者中提供了良好结局和停止治疗的路径。
  • 作者认为,超高危多发性骨髓瘤患者(≥2个高危染色体异常)的结局仍不令人满意,应优先纳入早期引入新机制作用药物的试验。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: For patients with newly diagnosed multiple myeloma, reaching minimal residual disease (MRD) negativity after treatment is associated with improved outcomes; however, the use of MRD to modulate therapy remains elusive. We present the final analysis of the MASTER trial of daratumumab, carfilzomib, lenalidomide, and dexamethasone (Dara-KRd) therapy in patients with newly diagnosed multiple myeloma, in which MRD status is used to modulate treatment duration and cessation. METHODS: MASTER was a multicentre, single-arm, phase 2 trial conducted in five academic medical centres in the USA. Eligible participants were 18 years or older with newly diagnosed multiple myeloma (measurable by serum or urine protein electrophoresis or serum free light chains), a life expectancy of at least 12 months, and an Eastern Cooperative Oncology Group performance status of 0-2, and had received no previous treatment for multiple myeloma except up to one cycle of therapy containing bortezomib, cyclophosphamide, and dexamethasone. The study was enriched for participants with high-risk chromosome abnormalities (HRCAs). During the induction phase, participants received four 28-day cycles of Dara-KRd, each comprising daratumumab (16 mg/kg intravenously on days 1, 8, 15, and 22), carfilzomib (56 mg/m2 intravenously on days 1, 8, and 15), lenalidomide (25 mg orally on days 1-21), and dexamethasone (40 mg orally or intravenously on days 1, 8, 15, and 22); induction was followed by autologous haematopoietic stem-cell transplantation and up to two phases of consolidation with Dara-KRd. We assessed MRD by next-generation sequencing after or during each phase. The primary endpoint was reaching MRD negativity (<10-5). Participants who reached MRD negativity after or during two consecutive phases stopped treatment and began observation with MRD surveillance (MRD-SURE); participants who did not reach two consecutive MRD-negative results received maintenance lenalidomide. Secondary endpoints included progression-free survival and cumulative incidence of progression. All analyses were conducted in the intention-to-treat population. This trial is registered with ClinicalTrials.gov, NCT03224507, and is complete. FINDINGS: Between Mar 21, 2018, and Oct 23, 2020, 123 participants were recruited to the study, of whom 70 (57%) were men, 53 (43%) were women, 94 (76%) were non-Hispanic White, 25 (20%) were non-Hispanic Black, and four (3%) were of another race or ethnicity. The median age of participants was 61 years (IQR 55-68), and 24 (20%) were aged 70 years or older. The median duration of follow up was 42·2 months (IQR 34·5-46·0). Of the 123 participants, 53 (43%) had no HRCAs, 46 (37%) had one HRCA, and 24 (20%) had two or more HRCAs. For 118 (96%) of 123 participants, MRD was evaluable by next-generation sequencing; the remaining five had an absence of sufficiently unique clonogenic sequences to enable tracking by the assay. Of these 118 participants, 96 (81%, 95% CI 73-88) reached MRD of less than 10-5 (comprising 39 [78%, 64-88] of 50 participants with no HRCAs, 38 [86%, 73-95] of 44 participants with one HRCA, and 19 [79%, 58-93] of 24 participants with two or more HRCAs) and 84 (71%, 62-79) reached MRD-SURE and treatment cessation. 36-month progression-free survival among all 123 participants was 88% (95% CI 78-95) for participants with no HRCAs, 79% (67-88) for those with one HRCA, and 50% (30-70) for those with two or more HRCAs. For the 84 participants reaching MRD-SURE, the 24-month cumulative incidence of progression from cessation of therapy was 9% (95% CI 1-19) for participants with no HRCAs, 9% (1-18) for those with one HRCA, and 47% (23-72) for those with two or more HRCAs. 61 participants (comprising 52% of 118 MRD-evaluable participants and 73% of 84 participants who reached MRD-SURE) remain free of therapy and MRD-negative as of Feb 7, 2023. The most common grade 3-4 adverse events were neutropenia (43 patients, 35%), lymphopenia (28 patients, 23%), and hypertension (13 patients, 11%). Three treatment-emergent deaths were recorded: two sudden deaths and one due to viral infection, none of which were judged to be treatment-related. INTERPRETATION: This approach provided positive outcomes and a pathway for treatment cessation in most patients with newly diagnosed multiple myeloma. Outcomes for patients with ultra-high-risk multiple myeloma, defined as those with two or more HRCAs, remain unsatisfactory, and these patients should be prioritised for trials with early introduction of therapies with novel mechanisms of action. FUNDING: Amgen and Janssen Pharmaceuticals.

来源:Lancet Haematol,查看原文。版权归原作者所有。

引用

  1. Costa LJ, Chhabra S, Medvedova E, et al. Minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma (MASTER): final report of the multicentre, single-arm, phase 2 trial. Lancet Haematol. 2023. PMID: 37776872. doi:10.1016/S2352-3026(23)00236-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。